Carole Monterrat
Keine laufenden Positionen mehr
Profil
Carole Monterrat worked as the Chief Financial Officer at Sopartec SA from 2014 to 2018 and as the Vice President-Resources at PROMETHERA Biosciences SA from 2009 to 2014.
She holds a doctorate from Université de Bordeaux and an MBA from Université Catholique de Louvain, which she received in 2008.
Ehemalige bekannte Positionen von Carole Monterrat
| Unternehmen | Position | Ende |
|---|---|---|
Sopartec SA
 Sopartec SA Investment ManagersFinance Sopartec SA is the investment and technology valorization arm of Université Catholique de Louvain (UCL) and was founded in 1942. Sopartec SA is headquartered in Louvain-la-Neuve, Belgium. | Finanzdirektor/CFO | 01.09.2018 |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Corporate Officer/Principal | 01.03.2014 |
Ausbildung von Carole Monterrat
| Université de Bordeaux | Doctorate Degree |
| Université Catholique de Louvain | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
Sopartec SA
Sopartec SA Investment ManagersFinance Sopartec SA is the investment and technology valorization arm of Université Catholique de Louvain (UCL) and was founded in 1942. Sopartec SA is headquartered in Louvain-la-Neuve, Belgium. | Finance |
